Division of Gastroenterology & Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Gastroenterology. 2012 Dec;143(6):1502-1509.e1. doi: 10.1053/j.gastro.2012.09.006. Epub 2012 Sep 11.
BACKGROUND & AIMS: The role of sphincter of Oddi manometry (SOM) in the management of patients with idiopathic recurrent acute pancreatitis requires clarification. We evaluated the therapeutic effects of endoscopic sphincterotomy in patients with recurrent acute pancreatitis and the prognostic significance of pancreatic sphincter dysfunction (SOD).
We performed a randomized trial of endoscopic retrograde cholangiopancreatography with SOM for patients with idiopathic recurrent acute pancreatitis. Patients with pancreatic SOD (n = 69) were assigned randomly to groups that received only biliary sphincterotomy (BES) or a combination of biliary and pancreatic sphincterotomy (DES); patients who underwent normal SOM (n = 20) were assigned randomly to groups that received BES or a sham surgery. The primary outcome was incidence of recurrent acute pancreatitis during the follow-up period (minimum, 1 year; maximum, 10 years). We also determined the incidence of chronic pancreatitis and analyzed factors associated with recurrence of acute pancreatitis.
Among the 69 patients with SOD, 48.5% who received BES and 47.2% who received DES had recurrent acute pancreatitis (95% confidence interval, -22.3 to 24.9; P = 1.0). In patients with normal SOM (n = 20), 27.3% of those who received BES and 11.1% of those who received the sham surgery had recurrent acute pancreatitis (95% confidence interval, -49.5 to 17.2; P = .59). Overall, 16.9% of subjects developed chronic pancreatitis during a median follow-up period of 78 months (interquartile range, 35-108 mo). The odds of recurrent acute pancreatitis during follow-up evaluation were significantly greater among patients with SOD than those with normal SOM (unadjusted hazard ratio, 3.5; 95% confidence interval, 1.07-11.4; P < .04), and remained so after adjusting for potential confounders (hazard ratio, 4.3; 95% confidence interval, 1.3-14.5; P < .02).
Among patients with pancreatic SOD, DES and BES have similar effects in preventing recurrence of acute pancreatitis. Pancreatic SOD is an independent prognostic factor, identifying patients at higher risk for recurrent acute pancreatitis.
Clinicaltrials.gov (NCT01583517).
Oddi 括约肌测压术(SOM)在特发性复发性急性胰腺炎管理中的作用尚需明确。我们评估了内镜下括约肌切开术治疗复发性急性胰腺炎的疗效和胰腺括约肌功能障碍(SOD)的预后意义。
我们对特发性复发性急性胰腺炎患者进行了 SOM 的内镜逆行胰胆管造影随机试验。有胰腺 SOD(n=69)的患者随机分为仅行胆管括约肌切开术(BES)或胆管和胰管括约肌切开术(DES)的两组;SOM 正常的患者(n=20)随机分为接受 BES 或假手术的两组。主要终点是随访期间(最短 1 年,最长 10 年)复发性急性胰腺炎的发生率。我们还确定了慢性胰腺炎的发生率,并分析了与急性胰腺炎复发相关的因素。
在 69 例 SOD 患者中,接受 BES 的患者中有 48.5%(95%置信区间,-22.3 至 24.9;P=1.0)和接受 DES 的患者中有 47.2%发生了复发性急性胰腺炎。SOM 正常的患者(n=20)中,接受 BES 的患者中有 27.3%和接受假手术的患者中有 11.1%发生了复发性急性胰腺炎(95%置信区间,-49.5 至 17.2;P=0.59)。在中位随访期 78 个月(四分位距,35-108 mo)期间,总体有 16.9%的受试者发展为慢性胰腺炎。与 SOM 正常的患者相比,SOD 患者在随访期间发生复发性急性胰腺炎的几率显著更高(未调整的危险比,3.5;95%置信区间,1.07-11.4;P<.04),调整潜在混杂因素后仍如此(危险比,4.3;95%置信区间,1.3-14.5;P<.02)。
在胰腺 SOD 患者中,DES 和 BES 在预防急性胰腺炎复发方面具有相似的效果。胰腺 SOD 是一个独立的预后因素,可识别出发生复发性急性胰腺炎风险更高的患者。
Clinicaltrials.gov(NCT01583517)。